CL

• Net sales increased 4.9% to $5,361 million in Q2 2026, with organic sales up 2.4%.
• GAAP diluted EPS decreased 5% to $0.86; Base Business EPS increased 8% to $0.99.
• Net cash provided by operations was $1,742 million for the first six months of 2026.
• Full-year 2026 guidance: net sales up 2% to 6%, organic sales growth 1% to 4%, and Base Business EPS growth now mid-single-digit.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Shareholders ratified PricewaterhouseCoopers LLP as independent auditor for 2026, with 647.4 million votes for and 53.0 million against.
• A non-binding advisory vote on executive compensation was approved, with 591.2 million votes for and 43.0 million against.
• A stockholder proposal to remove DEI from board candidate considerations was not approved, with 618.3 million votes against.
• A stockholder proposal for an independent board chairman was not approved, with 452.4 million votes against.

5.07 Submission of Matters to a Vote of Security Holders

• GAAP diluted EPS decreased 6% to $0.80, while Base Business diluted EPS increased 7% to $0.97.
• GAAP gross profit margin decreased 20 basis points to 60.6%.
• Net cash provided by operations was $747 million for the first three months of 2026.
• The company maintained its sales and EPS guidance but now expects gross profit margin to be down for full year 2026.

2.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 9.01 Financial Statements and Exhibits

• Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, intends to retire from the Company in 2026.
• On April 8, 2026, the Board elected Betsy Fishbone, currently EVP and Deputy Chief Legal Officer, to succeed Daniels as Chief Legal Officer and Secretary, effective June 1, 2026.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• Effective for the quarter ending March 31, 2026, Colgate-Palmolive will combine its Europe and Africa/Eurasia (excluding Russia and Belarus) segments with its Skin Health business (previously in North America) into a new Europe, Middle East and Africa reportable segment.
• The realignment is part of the previously announced Strategic Growth and Productivity Program to optimize operating scale and drive growth in Europe and Africa/Eurasia regions.
• The change has no impact on historical consolidated results of operations, financial position, or cash flows.
• The company recast historical segment information for 2023-2025 and interim 2025 periods, filed as Exhibit 99.

8.01 Other Events · 9.01 Financial Statements and Exhibits

• Christopher S. Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb, was elected to the Colgate-Palmolive Board effective March 15, 2026.
• He will receive compensation as a non-employee director under Colgate-Palmolive's director compensation program.
• Steven A. Cahillane will not stand for reelection at the Annual Meeting on May 8, 2026, due to his new role as CEO of The Kraft Heinz Company.
• The changes were reported on March 12, 2026.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• Full year GAAP diluted EPS declined 25% to $2.63, while Base Business EPS increased 3% to $3.69.
• Fourth quarter net sales increased 5.8% to $5,230 million, with organic sales growth of 2.2%.
• Fourth quarter GAAP diluted EPS was $(0.05), down 106%, due to a $794 million non-cash after-tax impairment charge on skin health business goodwill and intangibles.
• For full year 2026, the company expects net sales growth of 2% to 6% and organic sales growth of 1% to 4%.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The Notes were issued on November 10, 2025 under an Indenture dated November 15, 1992 with The Bank of New York Mellon as trustee.
• The offering was made under the company's automatic shelf registration statement on Form S-3 (File No. 333-275201) filed with the SEC on October 27, 2023, with a Prospectus Supplement filed on November 5, 2025.
• The underwriting agreement includes customary representations, warranties, covenants, and indemnification provisions.
• The report was filed under Item 8.01 as an other event to disclose the debt offering and related exhibits.

8.01 Other Events · 9.01 Financial Statements and Exhibits